CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. ...
| LSTA Stock | USD 3.73 0.02 0.54% |
About 50% of Lisata Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Lisata Therapeutics suggests that some traders are interested. The current market sentiment, together with Lisata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lisata Therapeutics stock news signals to limit their universe of possible portfolio assets.
Lisata |
PR NewswireNEW YORK, Jan. 2, 2025 NEW YORK, Jan. 2, 2025 PRNewswire -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class
Read at gurufocus.com
 |
Lisata Therapeutics Fundamental Analysis
We analyze Lisata Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lisata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lisata Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Lisata Therapeutics is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Lisata Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lisata Therapeutics stock to make a market-neutral strategy. Peer analysis of Lisata Therapeutics could also be used in its relative valuation, which is a method of valuing Lisata Therapeutics by comparing valuation metrics with similar companies.
Peers
Lisata Therapeutics Related Equities
| TPST | Tempest Therapeutics | 10.47 | ||||
| RZLT | Rezolute | 4.22 | ||||
| LIXT | Lixte Biotechnology | 3.00 | ||||
| MBRX | Moleculin Biotech | 1.13 | ||||
| XOMAO | XOMA | 0.32 | ||||
| PULM | Pulmatrix | 0.48 | ||||
| BPTH | Bio Path | 1.83 | ||||
| ANTX | AN2 Therapeutics | 2.17 | ||||
| PTIX | Protagenic Therapeutics | 3.39 | ||||
| IMNN | Imunon | 3.92 | ||||
| CADL | Candel Therapeutics | 4.02 | ||||
| GLUE | Monte Rosa | 5.22 |
Complementary Tools for Lisata Stock analysis
When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |